Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

  1. Efstratios Gavriilidis
  2. Christina Antoniadou
  3. Akrivi Chrysanthopoulou
  4. Maria Ntinopoulou
  5. Andreas Smyrlis
  6. Iliana Fotiadou
  7. Nikoleta Zioga
  8. Dionysios Kogias
  9. Anastasia-Maria Natsi
  10. Christos Pelekoudas
  11. Evangelia Satiridou
  12. Stefania-Aspasia Bakola
  13. Charalampos Papagoras
  14. Ioannis Mitroulis
  15. Paschalis Peichamperis
  16. Dimitrios Mikroulis
  17. Vasileios Papadopoulos
  18. Panagiotis Skendros
  19. Konstantinos Ritis

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.clim.2022.109016
  2. ScreenIT

    SciScore for 10.1101/2022.03.14.22270915: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Inclusion criteria were as follows: 1) adult patients ≥18 years old, of any gender, 2) positive polymerase-chain-reaction (PCR) test for SARS-CoV-2 RNA in nasopharyngeal swab, 3) pulmonary infiltrates suggestive of COVID-19, 4) SRF as defined by PaO2/FiO2<100 mmHg, 4) written informed consent from the patients or legal representatives for the current compassionate therapeutic protocol.
    IRB: The study protocol design was approved by the local scientific and ethics committees and institutional review board of the University Hospital of Alexandroupolis (Ref. No. 87/08-04-2020).
    Sex as a biological variablenot detected.
    RandomizationFor that purpose, all scale variables were turned into binary ones with the use of Optimal Scaling along with ridge regression, random initial configuration and bootstrapping.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Statistical analysis was performed using SPSS 26.0 software.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT05279391RecruitingCombination of Inhaled DNase, Baricitinib and Tocilizumab in…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.03.14.22270915 on medRxiv